Clinical Evidence

With more than 45 years of research, development, and published clinical studies, Nourkrin® is recognised by scientists, doctors, dermatologists and trichologists worldwide – making Nourkrin® the uncontested market leader in its category globally.

Nourkrin® continues to partner with the world’s leading authorities on hair loss and hair thinning, based on its clinically documented efficacy and safety standards.

Years of clinical research into the role of proteoglycans in hair follicle regulation.

35.7

Increase in hair density after 6 months treatment with Nourkrin® with Marilex®

Reported significant improvement in their hair growth after 12 months.

The results of +45 years of dedicated clinical research into the role of proteoglycans in hair follicle regulation:

Research Heritage

The beginning of the research heritage on the role of proteoglycans.

Scientific Breakthrough

Discovery of the modulatory role of specific biological macromolecules in hair follicle morphogenesis and cycling.

Proteoglycan Research

Research and development activities in Denmark, Sweden, and Norway were dedicated to dermal-derived proteoglycan research.

Marilex® Development

Identification of follicular concentration-dependent proteoglycans in hair follicle cycling, leading to the development of extraction and separation techniques and the first-generation proteoglycan complex (Marilex®), followed by the launch of Nourkrin®.

Commence of Clinical Trails

Proof of concept was established through a series of pilot and controlled human trials

Proof of Efficacy

A clinical study demonstrated increased hair growth rates in 75% of patients, indicating enhanced follicular cell proliferation following Nourkrin® treatment.

Production Scale-Up

Proprietary enzyme-assisted extraction and scale-up production techniques were established.

Proof of Hair Density

A controlled clinical study of Nourkrin® with Marilex® monotherapy demonstrated a significant improvement in hair density, with a 35.7% increase in hair count.

Clinical Confirmation

A 100-patient monotherapy study of Nourkrin® with Marilex® demonstrated further clinical efficacy.

Next Generation

The sixth generation of Marilex® was optimised for enhanced bioavailability and targeted delivery of scalp-modulatory proteoglycans.

Marilex®-M Development

Research and development commenced on Marilex®-M for Nourkrin® Man, targeting DHT-driven follicular miniaturisation in Male Pattern Hair Loss.

Pathology Identification

Proteoglycan Follicular Atrophy (PFA) was established as a major underlying pathology in male and female alopecia treated with Nourkrin® with Marilex®.

Ongoing Research

Ongoing global research is investigating the efficacy of Proteoglycan Replacement Therapy.

Since 1978, Nourkrin® and its specific biologically active proteoglycans have been the subject of more than 100 published clinical and scientific research studies: